BridgeBio Pharma (BBIO)
BridgeBio Pharma on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
20.0M
Short interest
settlement 2026-10-15
7.7
Days to cover
+1.8 days vs prior
72.4%
Short share of volume
2026-10-28
5,445
Fails to deliver
settlement 2026-09-18
Mon 11 Jan
Next earnings
estimated date
-$4.4M
Insider flow, 90 days
0 buys, 9 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in BBIO is 19,997,556 shares, down 1,551,793 shares over the last month. Over the last 48 readings it ranged from 16,998,642 shares (29 November 2024) to 25,750,649 shares (15 July 2026). At the reported average volume of 2.6M shares a day that is 7.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bbio" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 19,997,556 | +1.7% | 2,603,763 | 7.68 |
| 2026-09-30 | 19,671,292 | -8.7% | 3,364,995 | 5.85 |
| 2026-09-15 | 21,549,349 | -1.4% | 2,044,711 | 10.54 |
| 2026-08-31 | 21,845,899 | -6.3% | 1,954,275 | 11.18 |
| 2026-08-14 | 23,324,059 | -0.1% | 2,161,484 | 10.79 |
| 2026-07-31 | 23,342,623 | -9.3% | 2,029,913 | 11.50 |
| 2026-07-15 | 25,750,649 | +6.8% | 4,789,357 | 5.38 |
| 2026-06-30 | 24,102,938 | -5.2% | 5,343,347 | 4.51 |
| 2026-06-15 | 25,415,150 | +4.2% | 2,966,678 | 8.57 |
| 2026-05-29 | 24,391,359 | +0.9% | 2,541,695 | 9.60 |
| 2026-05-15 | 24,163,037 | +0.6% | 2,766,467 | 8.73 |
| 2026-04-30 | 24,026,982 | +6.0% | 3,164,946 | 7.59 |
| 2026-04-15 | 22,676,856 | -3.0% | 1,658,075 | 13.68 |
| 2026-03-31 | 23,366,752 | -0.6% | 1,586,799 | 14.73 |
| 2026-03-13 | 23,505,637 | +7.0% | 2,627,181 | 8.95 |
| 2026-02-27 | 21,964,843 | +3.8% | 3,144,750 | 6.98 |
| 2026-02-13 | 21,167,249 | +5.9% | 3,747,599 | 5.65 |
| 2026-01-30 | 19,980,855 | +8.8% | 2,796,641 | 7.14 |
| 2026-01-15 | 18,370,031 | +6.7% | 3,108,552 | 5.91 |
| 2025-12-31 | 17,211,114 | -8.4% | 1,689,124 | 10.19 |
| 2025-12-15 | 18,793,079 | -3.0% | 1,846,092 | 10.18 |
| 2025-11-28 | 19,381,854 | -6.3% | 2,283,542 | 8.49 |
| 2025-11-14 | 20,691,850 | +5.8% | 2,079,619 | 9.95 |
| 2025-10-31 | 19,566,757 | +12.8% | 2,991,207 | 6.54 |
| 2025-10-15 | 17,353,906 | -0.8% | 1,972,595 | 8.80 |
| 2025-09-30 | 17,486,250 | -10.1% | 2,428,656 | 7.20 |
| 2025-09-15 | 19,444,136 | -2.3% | 2,237,940 | 8.69 |
| 2025-08-29 | 19,909,858 | -2.8% | 2,213,867 | 8.99 |
| 2025-08-15 | 20,486,167 | +10.6% | 3,635,018 | 5.64 |
| 2025-07-31 | 18,519,082 | -4.9% | 1,951,249 | 9.49 |
| 2025-07-15 | 19,475,283 | -10.8% | 2,765,361 | 7.04 |
| 2025-06-30 | 21,834,552 | +3.4% | 4,101,770 | 5.32 |
| 2025-06-13 | 21,119,414 | -4.0% | 2,579,998 | 8.19 |
| 2025-05-30 | 21,990,968 | -1.8% | 2,171,004 | 10.13 |
| 2025-05-15 | 22,397,501 | +1.0% | 3,621,805 | 6.18 |
| 2025-04-30 | 22,179,814 | -0.6% | 3,135,833 | 7.07 |
| 2025-04-15 | 22,312,587 | +2.8% | 3,034,782 | 7.35 |
| 2025-03-31 | 21,707,824 | -0.2% | 2,408,907 | 9.01 |
| 2025-03-14 | 21,759,460 | -1.8% | 3,179,373 | 6.84 |
| 2025-02-28 | 22,155,112 | +9.8% | 4,582,307 | 4.83 |
| 2025-02-14 | 20,183,599 | +7.5% | 2,335,322 | 8.64 |
| 2025-01-31 | 18,776,419 | -7.9% | 2,439,034 | 7.70 |
| 2025-01-15 | 20,382,829 | +5.6% | 3,389,666 | 6.01 |
| 2024-12-31 | 19,299,148 | +12.7% | 1,749,289 | 11.03 |
| 2024-12-13 | 17,124,130 | +0.7% | 1,639,583 | 10.44 |
| 2024-11-29 | 16,998,642 | -1.1% | 3,631,652 | 4.68 |
| 2024-11-15 | 17,187,425 | -0.1% | 1,828,212 | 9.40 |
| 2024-10-31 | 17,199,451 | -3.3% | 1,268,097 | 13.56 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of BBIO volume is 72.4%, down 3.3 points over the last five sessions. Over the last 30 readings it ranged from 31.9% (25 September 2026) to 75.7% (21 October 2026). The latest reading sits at the top of that range. The latest reading is 18.7 points above the 30-session average of 53.7%, on 1.5M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 1.1M | 1.5M | 72.4% | 2 |
| 2026-10-27 | 756K | 1.1M | 71.3% | 1 |
| 2026-10-26 | 305K | 631K | 48.3% | 51 |
| 2026-10-23 | 648K | 966K | 67.1% | 13,547 |
| 2026-10-22 | 431K | 991K | 43.5% | 0 |
| 2026-10-21 | 1.2M | 1.6M | 75.7% | 15 |
| 2026-10-20 | 750K | 1.2M | 61.3% | 0 |
| 2026-10-19 | 316K | 664K | 47.7% | 0 |
| 2026-10-16 | 543K | 906K | 59.9% | 31 |
| 2026-10-15 | 492K | 1.1M | 44.9% | 2 |
| 2026-10-14 | 406K | 906K | 44.8% | 210 |
| 2026-10-13 | 620K | 1.2M | 52.0% | 24 |
| 2026-10-12 | 398K | 709K | 56.2% | 1 |
| 2026-10-09 | 277K | 731K | 37.9% | 0 |
| 2026-10-08 | 539K | 1.1M | 48.2% | 2,000 |
| 2026-10-07 | 356K | 720K | 49.4% | 0 |
| 2026-10-06 | 1.0M | 2.0M | 50.7% | 110,000 |
| 2026-10-05 | 483K | 697K | 69.3% | 13,300 |
| 2026-10-02 | 714K | 1.1M | 66.9% | 0 |
| 2026-10-01 | 884K | 1.5M | 58.7% | 613 |
| 2026-09-30 | 476K | 1.0M | 47.1% | 4,180 |
| 2026-09-29 | 907K | 1.7M | 52.4% | 0 |
| 2026-09-28 | 826K | 1.4M | 59.7% | 0 |
| 2026-09-25 | 252K | 788K | 31.9% | 0 |
| 2026-09-24 | 1.4M | 2.5M | 54.8% | 0 |
| 2026-09-23 | 1.1M | 2.0M | 53.1% | 17 |
| 2026-09-22 | 628K | 1.6M | 38.3% | 57 |
| 2026-09-21 | 1.0M | 1.7M | 57.7% | 19,260 |
| 2026-09-18 | 445K | 876K | 50.9% | 0 |
| 2026-09-17 | 409K | 1.1M | 38.5% | 1,207 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 18 September 2026, the fails-to-deliver balance in BBIO is 5,445 shares, down 44,728 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (8 September 2026) to 1,697,839 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-18 | 5,445 | $67.31 | $367K |
| 2026-09-14 | 50,173 | $72.44 | $3.6M |
| 2026-09-11 | 105 | $72.50 | $8K |
| 2026-09-10 | 283 | $76.08 | $22K |
| 2026-09-08 | 2 | $74.84 | $150 |
| 2026-09-04 | 123 | $75.41 | $9K |
| 2026-09-02 | 4,996 | $76.57 | $383K |
| 2026-08-25 | 57 | $81.07 | $5K |
| 2026-08-24 | 35 | $81.50 | $3K |
| 2026-08-05 | 15,279 | $82.07 | $1.3M |
| 2026-07-28 | 10 | $84.12 | $841 |
| 2026-07-24 | 100 | $82.93 | $8K |
| 2026-07-23 | 100 | $82.66 | $8K |
| 2026-07-22 | 100 | $82.45 | $8K |
| 2026-07-20 | 185 | $81.38 | $15K |
| 2026-07-17 | 4 | $80.30 | $321 |
| 2026-07-08 | 7,800 | $77.91 | $608K |
| 2026-07-01 | 60 | $74.48 | $4K |
| 2026-06-30 | 1,697,839 | $72.01 | $122.3M |
| 2026-06-29 | 1,647,278 | $70.24 | $115.7M |
| 2026-06-26 | 93 | $69.69 | $6K |
| 2026-06-25 | 522 | $69.36 | $36K |
| 2026-06-15 | 187 | $66.80 | $12K |
| 2026-06-05 | 7 | $67.33 | $471 |
| 2026-06-02 | 28,830 | $65.36 | $1.9M |
| 2026-05-29 | 390 | $68.45 | $27K |
| 2026-05-19 | 68 | $65.32 | $4K |
| 2026-05-13 | 8 | $65.95 | $528 |
| 2026-05-11 | 13 | $67.39 | $876 |
| 2026-05-08 | 3,016 | $67.45 | $203K |
Insider trades
SEC Form 4, newest first. JSONInsiders at BBIO reported 9 open-market sells worth $4.4M in the last 90 days and no open-market buys. Latest filing: Kumar Neil (Chief Executive Officer) on 2026-09-17.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Kumar Neil | Chief Executive Officer | Sell | 1K | $69.57 | $89K | 496K |
| 2026-09-17 | Kumar Neil | Chief Executive Officer | Sell | 9K | $69.01 | $602K | 497K |
| 2026-08-19 | Kumar Neil | Chief Executive Officer | Sell | 100 | $85.65 | $9K | 506K |
| 2026-08-19 | Kumar Neil | Chief Executive Officer | Sell | 2K | $84.69 | $152K | 506K |
| 2026-08-19 | Kumar Neil | Chief Executive Officer | Sell | 8K | $83.86 | $679K | 508K |
| 2026-08-18 | Kumar Neil | Chief Executive Officer | Sell | 1K | $83.77 | $100K | 243K |
| 2026-08-18 | Kumar Neil | Chief Executive Officer | Sell | 15K | $82.99 | $1.2M | 245K |
| 2026-08-18 | Kumar Neil | Chief Executive Officer | Sell | 17K | $82.21 | $1.4M | 259K |
| 2026-08-18 | Kumar Neil | Chief Executive Officer | Sell | 2K | $81.15 | $154K | 276K |
| 2026-08-16 | Kumar Neil | Chief Executive Officer | Tax withholding | 36K | $79.86 | $2.9M | 278K |
| 2026-08-16 | Kumar Neil | Chief Executive Officer | Exercise or conversion | 7K | price not stated in the filing | not stated | 315K |
| 2026-08-16 | Kumar Neil | Chief Executive Officer | Exercise or conversion | 12K | price not stated in the filing | not stated | 308K |
| 2026-08-16 | Kumar Neil | Chief Executive Officer | Exercise or conversion | 20K | price not stated in the filing | not stated | 296K |
| 2026-08-16 | Kumar Neil | Chief Executive Officer | Exercise or conversion | 34K | price not stated in the filing | not stated | 277K |
| 2026-08-16 | Trimarchi Thomas | President and CFO | Tax withholding | 23K | $79.86 | $1.8M | 337K |
| 2026-08-16 | Apuli Maricel | Chief Accounting Officer | Tax withholding | 5K | $79.86 | $376K | 123K |
| 2026-07-30 | Apuli Maricel | Chief Accounting Officer | Sell | 2K | $80.06 | $160K | 127K |
| 2026-07-09 | Ellis Andrea | Director | Sell | 17K | $84.00 | $1.4M | 23K |
| 2026-07-09 | Ellis Andrea | Director | Exercise or conversion | 17K | $16.75 | $288K | 40K |
| 2026-07-09 | Cook Jennifer E. | Director | Sell | 112K | $90.00 | $10.1M | 8K |
| 2026-07-09 | Cook Jennifer E. | Director | Sell | 36K | $84.00 | $3.0M | 121K |
| 2026-07-09 | Cook Jennifer E. | Director | Exercise or conversion | 17K | $16.75 | $288K | 157K |
| 2026-07-09 | Cook Jennifer E. | Director | Exercise or conversion | 112K | $29.00 | $3.3M | 140K |
| 2026-07-09 | Cook Jennifer E. | Director | Exercise or conversion | 19K | $8.45 | $161K | 27K |
| 2026-06-24 | Cook Jennifer E. | Director | Sell | 37K | $70.00 | $2.6M | 8K |
| 2026-06-24 | Cook Jennifer E. | Director | Exercise or conversion | 17K | $16.75 | $288K | 46K |
| 2026-06-24 | Cook Jennifer E. | Director | Exercise or conversion | 20K | $8.45 | $169K | 28K |
| 2026-06-23 | Cook Jennifer E. | Director | Sell | 2K | $68.57 | $151K | 8K |
| 2026-06-23 | Valantine Hannah | Director | Sell | 2K | $68.57 | $151K | 9K |
| 2026-06-22 | Cook Jennifer E. | Director | Grant | 4K | $0.00 | $0 | 11K |
| 2026-06-22 | Valantine Hannah | Director | Sell | 3K | $68.00 | $191K | 11K |
| 2026-06-22 | Valantine Hannah | Director | Exercise or conversion | 3K | $41.73 | $117K | 14K |
| 2026-06-22 | Valantine Hannah | Director | Grant | 4K | $0.00 | $0 | 11K |
| 2026-06-22 | Lo Andrew | Director | Grant | 4K | $0.00 | $0 | 18K |
| 2026-06-22 | HOMCY CHARLES J | Director | Grant | 4K | $0.00 | $0 | 920K |
| 2026-06-22 | DANIELS RONALD J | Director | Grant | 4K | $0.00 | $0 | 21K |
| 2026-06-22 | Ellis Andrea | Director | Grant | 4K | $0.00 | $0 | 23K |
| 2026-06-22 | Hassan Fred | Director | Grant | 4K | $0.00 | $0 | 30K |
| 2026-06-22 | MOMTAZEE JAMES C | Director | Grant | 4K | $0.00 | $0 | 19K |
| 2026-06-22 | MCCORMICK FRANK | Director | Grant | 4K | $0.00 | $0 | 11K |
| 2026-06-22 | Dachille Douglas A. | Director | Grant | 4K | $0.00 | $0 | 11K |
| 2026-06-22 | Satvat Ali J. | Director | Grant | 4K | $0.00 | $0 | 170K |
| 2026-06-22 | AGUIAR ERIC | Director | Grant | 4K | $0.00 | $0 | 11K |
| 2026-06-20 | HOMCY CHARLES J | Director | Tax withholding | 788 | $66.27 | $52K | 916K |
| 2026-06-15 | Cook Jennifer E. | Director | Sell | 89K | $66.62 | $5.9M | 8K |
| 2026-06-15 | Cook Jennifer E. | Director | Exercise or conversion | 17K | $16.75 | $288K | 97K |
| 2026-06-15 | Cook Jennifer E. | Director | Exercise or conversion | 66K | $8.45 | $557K | 80K |
| 2026-06-15 | Cook Jennifer E. | Director | Sell | 2K | $67.14 | $101K | 7K |
| 2026-06-05 | Kumar Neil | Chief Executive Officer | Sell | 8K | $67.88 | $573K | 4.3M |
| 2026-06-05 | Kumar Neil | Chief Executive Officer | Sell | 4K | $68.96 | $304K | 4.3M |
| 2026-06-05 | Kumar Neil | Chief Executive Officer | Sell | 7K | $67.20 | $480K | 4.3M |
| 2026-06-05 | Kumar Neil | Chief Executive Officer | Sell | 4K | $68.96 | $305K | 516K |
| 2026-06-05 | Kumar Neil | Chief Executive Officer | Sell | 8K | $67.88 | $573K | 520K |
| 2026-06-05 | Kumar Neil | Chief Executive Officer | Sell | 7K | $67.20 | $480K | 529K |
| 2026-06-04 | Kumar Neil | Chief Executive Officer | Sell | 450 | $68.27 | $31K | 4.3M |
| 2026-06-04 | Kumar Neil | Chief Executive Officer | Sell | 16K | $67.74 | $1.1M | 4.3M |
| 2026-06-04 | Kumar Neil | Chief Executive Officer | Sell | 1K | $66.72 | $95K | 4.4M |
| 2026-06-04 | Kumar Neil | Chief Executive Officer | Sell | 2K | $65.72 | $145K | 4.4M |
| 2026-06-04 | Kumar Neil | Chief Executive Officer | Sell | 450 | $68.27 | $31K | 536K |
| 2026-06-04 | Kumar Neil | Chief Executive Officer | Sell | 16K | $67.74 | $1.1M | 536K |
| 2026-06-04 | Kumar Neil | Chief Executive Officer | Sell | 1K | $66.72 | $95K | 552K |
| 2026-06-04 | Kumar Neil | Chief Executive Officer | Sell | 2K | $65.72 | $145K | 553K |
| 2026-05-21 | Kumar Neil | Chief Executive Officer | Sell | 800 | $70.92 | $57K | 243K |
| 2026-05-21 | Kumar Neil | Chief Executive Officer | Sell | 11K | $70.48 | $793K | 244K |
| 2026-05-21 | Kumar Neil | Chief Executive Officer | Sell | 5K | $69.22 | $351K | 255K |
| 2026-05-21 | Kumar Neil | Chief Executive Officer | Sell | 7K | $68.30 | $459K | 260K |
| 2026-05-21 | Kumar Neil | Chief Executive Officer | Sell | 2K | $67.57 | $152K | 267K |
| 2026-05-18 | Trimarchi Thomas | President and CFO | Sell | 3K | $65.95 | $211K | 359K |
| 2026-05-18 | Trimarchi Thomas | President and CFO | Sell | 10K | $64.82 | $678K | 362K |
| 2026-05-16 | Kumar Neil | Chief Executive Officer | Exercise or conversion | 12K | price not stated in the filing | not stated | 299K |
| 2026-05-16 | Kumar Neil | Chief Executive Officer | Exercise or conversion | 7K | price not stated in the filing | not stated | 306K |
| 2026-05-16 | Kumar Neil | Chief Executive Officer | Tax withholding | 36K | $66.13 | $2.4M | 269K |
| 2026-05-16 | Kumar Neil | Chief Executive Officer | Exercise or conversion | 20K | price not stated in the filing | not stated | 288K |
| 2026-05-16 | Kumar Neil | Chief Executive Officer | Exercise or conversion | 34K | price not stated in the filing | not stated | 268K |
| 2026-05-16 | Trimarchi Thomas | President and CFO | Tax withholding | 23K | $66.13 | $1.5M | 373K |
| 2026-05-16 | Apuli Maricel | Chief Accounting Officer | Tax withholding | 5K | $66.13 | $312K | 129K |
| 2026-05-15 | Scott Randal W. | Director | Sell | 200 | $69.12 | $14K | 12K |
| 2026-05-15 | Scott Randal W. | Director | Sell | 2K | $68.23 | $103K | 12K |
| 2026-05-15 | Scott Randal W. | Director | Sell | 2K | $67.53 | $141K | 13K |
| 2026-05-15 | Scott Randal W. | Director | Sell | 6K | $66.69 | $413K | 15K |
| 2026-05-15 | Scott Randal W. | Director | Exercise or conversion | 10K | $16.75 | $168K | 22K |
| 2026-05-08 | Kumar Neil | Chief Executive Officer | Sell | 950 | $68.35 | $65K | 4.4M |
| 2026-05-08 | Kumar Neil | Chief Executive Officer | Sell | 5K | $67.35 | $342K | 4.4M |
| 2026-05-08 | Kumar Neil | Chief Executive Officer | Sell | 14K | $66.65 | $931K | 4.4M |
| 2026-05-08 | Kumar Neil | Chief Executive Officer | Sell | 950 | $68.35 | $65K | 556K |
| 2026-05-08 | Kumar Neil | Chief Executive Officer | Sell | 5K | $67.35 | $342K | 557K |
| 2026-05-08 | Kumar Neil | Chief Executive Officer | Sell | 14K | $66.65 | $931K | 562K |
| 2026-05-07 | Kumar Neil | Chief Executive Officer | Sell | 11K | $67.49 | $757K | 4.4M |
| 2026-05-07 | Kumar Neil | Chief Executive Officer | Sell | 449 | $69.09 | $31K | 4.4M |
| 2026-05-07 | Kumar Neil | Chief Executive Officer | Sell | 8K | $68.38 | $570K | 4.4M |
| 2026-05-07 | Kumar Neil | Chief Executive Officer | Sell | 450 | $69.09 | $31K | 576K |
| 2026-05-07 | Kumar Neil | Chief Executive Officer | Sell | 8K | $68.38 | $570K | 576K |
| 2026-05-07 | Kumar Neil | Chief Executive Officer | Sell | 11K | $67.50 | $757K | 584K |
| 2026-04-30 | Apuli Maricel | Chief Accounting Officer | Sell | 2K | $71.58 | $143K | 134K |
| 2026-04-10 | Kumar Neil | Chief Executive Officer | Sell | 20K | $74.60 | $1.5M | 4.4M |
| 2026-04-10 | Kumar Neil | Chief Executive Officer | Sell | 20K | $74.60 | $1.5M | 596K |
| 2026-04-09 | Kumar Neil | Chief Executive Officer | Sell | 8K | $75.53 | $589K | 4.4M |
| 2026-04-09 | Kumar Neil | Chief Executive Officer | Sell | 5K | $74.57 | $382K | 4.4M |
| 2026-04-09 | Kumar Neil | Chief Executive Officer | Sell | 7K | $73.64 | $521K | 4.4M |
| 2026-04-09 | Kumar Neil | Chief Executive Officer | Sell | 8K | $75.55 | $567K | 616K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON35 Form 144 notices on file for BBIO worth $123.4M at the prices reported; 3 in the last 90 days worth $7.0M. Latest: KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 filed on 2026-08-19 to sell 30,000 shares ($2.5M) from 2026-08-19.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-19 | KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019Director, Officer | 30K | $2.5M | 0.015% | 2026-08-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-18 | NEIL KUMARDirector, Officer | 35K | $2.8M | 0.018% | 2026-08-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | RANDAL SCOTTDirector | 22K | $1.7M | 0.011% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-09 | JENNIFER COOKDirector | 149K | $13.2M | 0.076% | 2026-07-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-09 | ANDREA ELLISDirector | 17K | $1.4M | 0.009% | 2026-07-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-24 | RANDAL SCOTTDirector | 2K | $151K | 0.001% | 2026-06-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-24 | JENNIFER COOKDirector | 37K | $2.6M | 0.019% | 2026-06-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | JENNIFER COOKDirector | 2K | $151K | 0.001% | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | HANNAH A VALANTINEDirector | 2K | $151K | 0.001% | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-22 | HANNAH A VALANTINEDirector | 3K | $191K | 0.001% | 2026-06-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-15 | JENNIFER COOKDirector | 90K | $6.0M | 0.046% | 2026-06-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-21 | NEIL KUMARDirector, Officer | 26K | $1.8M | 0.013% | 2026-05-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-18 | THOMAS TRIMARCHIOfficer | 14K | $888K | 0.007% | 2026-05-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-09 | KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018Director, Officer | 120K | $8.9M | 0.062% | 2026-04-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-13 | KUMAR HALDEA FAMILY IRREVOCABLE TRUSTDirector, Officer | 140K | $9.5M | 0.072% | 2026-03-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-10 | HANNAH A VALANTINEDirector | 9K | $624K | 0.004% | 2026-03-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | ANDREA ELLISDirector | 65K | $4.2M | 0.033% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-27 | HANNAH A VALANTINEDirector | 25K | $1.7M | 0.013% | 2026-02-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-19 | NEIL KUMARDirector, Officer | 28K | $2.1M | 0.015% | 2026-02-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-17 | RANDAL SCOTTDirector | 20K | $1.5M | 0.010% | 2026-02-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-17 | THOMAS TRIMARCHIOfficer | 14K | $1.0M | 0.007% | 2026-02-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-08 | KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018Director, Officer | 120K | $8.9M | 0.062% | 2026-01-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-08 | KUMAR HALDEA FAMILY IRREVOCABLE TRUSTDirector, Officer | 100K | $7.4M | 0.052% | 2026-01-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | NEIL KUMARDirector, Officer | 30K | $2.3M | 0.016% | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-20 | NEIL KUMARDirector, Officer | 26K | $1.7M | 0.014% | 2025-11-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-18 | ANDREW W LODirector | 55K | $3.6M | 0.029% | 2025-11-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-17 | ANDREW W LODirector | 41K | $2.7M | 0.021% | 2025-11-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-17 | RANDAL SCOTTDirector | 10K | $664K | 0.005% | 2025-11-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-17 | THOMAS TRIMARCHIOfficer | 17K | $1.1M | 0.009% | 2025-11-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-12 | Hannah A ValantineDirector | 25K | $1.7M | 0.013% | 2025-11-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-06 | RONALD J DANIELSDirector | 61K | $3.9M | 0.032% | 2025-11-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-29 | Frank McCormickDirector | 198K | $13.2M | 0.104% | 2025-10-29 | Merrill Lynch |
| 2025-10-27 | Frank McCormickDirector | 2K | $107K | 0.001% | 2025-10-27 | Merrill Lynch |
| 2025-10-08 | KUMAR HALDEA FAMILY IRREVOCABLE TRUSTDirector, Officer | 120K | $6.5M | 0.063% | 2025-10-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-08 | KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018Director, Officer | 120K | $6.5M | 0.063% | 2025-10-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 56 shown. JSON26 holders report 5% or more of BBIO in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is JANUS HENDERSON GROUP PLC at 6.8% of the class (13,179,013 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G | BlackRock, Inc.parent holding company | 9.9M | 5.1% | 2026-09-30 |
| 2026-08-17 | 13D/Ano. 7 | Henry R. Kravisindividual | 9.2M | 4.7% | 2026-08-13 |
| 2026-08-17 | 13D/Ano. 7 | George R. Robertsindividual | 9.2M | 4.7% | 2026-08-13 |
| 2026-08-17 | 13D/Ano. 7 | KKR Group Holdings Corp.corporation | 9.2M | 4.7% | 2026-08-13 |
| 2026-08-17 | 13D/Ano. 7 | KKR Management LLPpartnership | 9.2M | 4.7% | 2026-08-13 |
| 2026-08-17 | 13D/Ano. 7 | KKR Group Co. Inc.corporation | 9.2M | 4.7% | 2026-08-13 |
| 2026-08-17 | 13D/Ano. 7 | KKR & Co. Inc.corporation | 9.2M | 4.7% | 2026-08-13 |
| 2026-08-17 | 13D/Ano. 7 | KKR Group Partnership L.P.partnership | 9.2M | 4.7% | 2026-08-13 |
| 2026-08-17 | 13D/Ano. 7 | KKR Genetic Disorder GP LLCother entity | 8.3M | 4.2% | 2026-08-13 |
| 2026-08-17 | 13D/Ano. 7 | KKR Genetic Disorder L.P.partnership | 8.3M | 4.2% | 2026-08-13 |
| 2026-08-03 | 13G/Ano. 1 | Spokes, Andrew J. M.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Warren, John R.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Wehrly, Mark C.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Capital Management, L.L.C.investment adviser, other entity | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Dapice Joshua J.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Dunn Hannah E.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Dreyfuss, Philip D.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Gehani, Varun N.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Giauque, Nicolasparent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Husen, Avner A.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Kim, David T.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Linn, Michael G.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Luo Patrick (Cheng)parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Roberts, Jr., Thomas G.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Saito Edric C.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Short Daniel S.parent holding company, individual | 10.7M | 5.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Healthcare Partners (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Healthcare Partners Master, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 1 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-07-10 | 13D/Ano. 12 | Shabet Rose Sharonindividual | 9.8M | 5.0% | 2026-07-09 |
| 2026-07-10 | 13D/Ano. 12 | HALVORSEN OLE ANDREASindividual | 9.8M | 5.0% | 2026-07-09 |
| 2026-07-10 | 13D/Ano. 12 | Viking Global Opportunities Illiquid Investments Sub-Master LPpartnership | 9.8M | 5.0% | 2026-07-09 |
| 2026-07-10 | 13D/Ano. 12 | Viking Global Opportunities Portfolio GP LLCother entity | 9.8M | 5.0% | 2026-07-09 |
| 2026-07-10 | 13D/Ano. 12 | Viking Global Opportunities GP LLCother entity | 9.8M | 5.0% | 2026-07-09 |
| 2026-07-10 | 13D/Ano. 12 | Viking Global Opportunities Parent GP LLCother entity | 9.8M | 5.0% | 2026-07-09 |
| 2026-07-10 | 13D/Ano. 12 | VIKING GLOBAL INVESTORS LPpartnership | 9.8M | 5.0% | 2026-07-09 |
| 2026-05-15 | 13G/Ano. 1 | JANUS HENDERSON GROUP PLCparent holding company | 13.2M | 6.8% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13D/Ano. 10 | Ott David C.individual | 13.0M | 6.8% | 2026-02-12 |
| 2025-11-14 | 13D/Ano. 9 | Viking Global Opportunities Liquid Portfolio Sub-Master LPpartnership | 0 | 0.0% | 2025-11-14 |
13F holders
Tracked managers holding BBIO at their latest 13F. JSON10 of the 30 tracked managers held BBIO at their latest 13F, $1.93B in total at quarter-end prices. Viking Global Investors is the largest at $741.0M (2.1% of its portfolio) as of 2026-06-30. Over the prior quarter 7 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Viking Global Investors | 2026-06-30 | 9.9M | $741.0M | 2.11% | -1.9M |
| Two Sigma Investments | 2026-06-30 | 4.7M | $351.7M | 0.25% | +1.6M |
| Citadel Advisors | 2026-06-30 | 3.8M | $280.0M | 0.03% | +586K |
| D. E. Shaw & Co. | 2026-06-30 | 3.6M | $270.6M | 0.13% | +1.1M |
| Point72 Asset Management | 2026-06-30 | 1.5M | $113.6M | 0.13% | new |
| Renaissance Technologies | 2026-06-30 | 857K | $63.8M | 0.09% | +491K |
| Millennium Management | 2026-06-30 | 488K | $36.3M | 0.01% | -146K |
| Bridgewater Associates | 2026-06-30 | 448K | $33.4M | 0.14% | +189K |
| Fisher Asset Management | 2026-06-30 | 345K | $25.7M | 0.01% | -6K |
| AQR Capital Management | 2026-06-30 | 167K | $12.4M | 0.00% | +7K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) BridgeBio Pharma reported revenue of $243.7M, up 120.4% from the same quarter a year earlier (-0.78 diluted EPS). In FY 2025 it generated -$445.9M of operating cash flow and spent $48.3M on buybacks. As of 2026-06-30, cash was $677.9M against $2.65B of debt.
- Cash
- $677.9M
- Debt
- $2.65B
- Equity
- -$2.52B
- Total assets
- $1.22B
- Shares outstanding
- 195,487,474
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $243.7M | n/a | n/a | -0.78 |
| Q1 FY 2026 | 2026-03-31 | $194.5M | n/a | n/a | -0.84 |
| Q4 FY 2025derived | 2025-12-31 | $154.2M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $120.7M | n/a | n/a | -0.95 |
| Q2 FY 2025 | 2025-06-30 | $110.6M | n/a | n/a | -0.95 |
| Q1 FY 2025 | 2025-03-31 | $116.6M | n/a | n/a | -0.88 |
| Q4 FY 2024derived | 2024-12-31 | $5.9M | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $2.7M | n/a | n/a | -0.86 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $502.1M | n/a | -$445.9M | $1.1M | $48.3M | n/a |
| FY 2024 | 2024-12-31 | $221.9M | n/a | -$520.7M | $933K | $0 | n/a |
| FY 2023 | 2023-12-31 | $9.3M | n/a | -$527.7M | $1.3M | $0 | n/a |
| FY 2022 | 2022-12-31 | $77.6M | n/a | -$419.5M | $4.8M | $0 | n/a |
| FY 2021 | 2021-12-31 | $69.7M | n/a | -$497.9M | $13.2M | $200.0M | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
BridgeBio Pharma in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows BridgeBio Pharma (BBIO), SEC CIK 1743881, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-18.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-19.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-10.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-17.JSON and CSV
- Company record
- EDGAR filing index for CIK 1743881Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of BBIO is sold short?
19,997,556 shares were held short at the 2026-10-15 settlement, 7.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is BBIO's daily short volume?
On 2026-10-28, 1,085,283 of the 1,498,647 BBIO shares reported to FINRA were sold short, 72.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does BBIO have fails to deliver?
The SEC's latest file shows 5,445 BBIO shares failed to deliver at settlement 2026-09-18. Fails are reported per settlement date and published twice a month with a lag.
Are BBIO insiders buying or selling?
Insiders at BBIO reported 9 open-market sells worth $4.4M in the last 90 days and no open-market buys. Latest filing: Kumar Neil (Chief Executive Officer) on 2026-09-17.
Have BBIO insiders filed to sell?
35 Form 144 notices on file for BBIO worth $123.4M at the prices reported; 3 in the last 90 days worth $7.0M. Latest: KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 filed on 2026-08-19 to sell 30,000 shares ($2.5M) from 2026-08-19.
Who owns 5% or more of BBIO?
26 holders report 5% or more of BBIO in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is JANUS HENDERSON GROUP PLC at 6.8% of the class (13,179,013 shares), filed 2026-05-15 for an event on 2026-03-31.
What did BBIO report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) BridgeBio Pharma reported revenue of $243.7M, up 120.4% from the same quarter a year earlier (-0.78 diluted EPS). In FY 2025 it generated -$445.9M of operating cash flow and spent $48.3M on buybacks. As of 2026-06-30, cash was $677.9M against $2.65B of debt.
Which tracked 13F managers own BBIO?
10 of the 30 tracked 13F managers held BBIO shares at their latest filing, $1.93B in all. The largest: Andreas Halvorsen's Viking Global Investors (9.9M shares, $741.0M), Two Sigma Investments (4.7M shares, $351.7M), Ken Griffin's Citadel Advisors (3.8M shares, $280.0M), D. E. Shaw & Co. (3.6M shares, $270.6M), Steve Cohen's Point72 Asset Management (1.5M shares, $113.6M), Renaissance Technologies (857K shares, $63.8M). The table above lists all 10.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.